Bleakley Financial Group
DNA icon

Bleakley Financial Group’s Ginkgo Bioworks DNA Stock Holding History

Bleakley Financial Group’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-279
Closed -$13K – 1031
2024
Q1 		$13K Sell
279
-53
-16% -$2.74K ﹤0.01% 993
2023
Q4 		$22.5K Buy
332
+74
+29% +$4.53K ﹤0.01% 941
2023
Q3 		$18.7K Sell
258
-153
-37% -$12.2K ﹤0.01% 873
2023
Q2 		$30.6K Buy
+411
New +$24.3K ﹤0.01% 909
2023
Q1 		– Sell
-357
Closed -$24.1K – 922
2022
Q4 		$24.1K Buy
+357
New +$32.8K ﹤0.01% 857

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Glenview Capital Management
Glenview Capital Management New York $5.49B AUM 46.89% 1-Year Est. Return
SB Investment Advisers (UK)
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Bleakley Financial Group's DNA Position: Q2 2024 in Review

Bleakley Financial Group sold out of Ginkgo Bioworks (DNA) in Q2 2024, closing a stake of 279 shares — an estimated $13K sold.

Bleakley Financial Group first reported a position in DNA in Q4 2022 and held it in 5 quarters. The position peaked at $30.6K in Q2 2023. 313 funds tracked by Wall St. Rank hold DNA as of Q2 2024.

  • Bleakley Financial Group reported no remaining Ginkgo Bioworks position as of Q2 2024 after selling out during the quarter.
  • Bleakley Financial Group sold 279 Ginkgo Bioworks shares in Q2 2024, an estimated $13K.
  • Bleakley Financial Group first reported a position in Ginkgo Bioworks in Q4 2022 and held it in 5 quarters.
  • Bleakley Financial Group's Ginkgo Bioworks position peaked at $30.6K in Q2 2023.
  • 313 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2024.

Based on Bleakley Financial Group's 13F filing for Q2 2024, filed 12 Aug 2024.